Several in vivo and in vitro studies demonstrated that the treatment with Her-2 neutralizing antibodies like Trastuzumab induced a down-regulation of VEGF mRNA and protein levels in Her-2-overexpressing tumors resected from xenografted mice as well as in Her-2 overexpressing breast tumor cell lines, associated with inhibition of tumor growth and vessel formation [49, 52]. The gene discussed is ERBB2; the disease is breast neoplasm.